Novel RNA Interference (RNAi)-Based Nanomedicines for Treating Viral Infections - Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications - page 207

Virus Drug Name RNAi Type Delivery Method Stage Reference

SARS N/A siRNA Intratracheal/Intranasal Rhesus Macaque [77]

HIV VRX496 asRNA Ex vivo lentiviral transduction Phase II ongoing [76]

rHIV7-shI-TAR-CCR5RZ shRNA Ex vivo lentiviral transduction Phase I completed [31]

HIV N/A shRNA Ex vivo lentiviral transduction Rhesus Macaque [2]

CCR5-ZZ-SIN shRNA targeted lentiviral transduction Hu-PBL mouse model [4]

scFVCD7-9R siRNA i.v. Hu-PBL, Hu-HSC mouse

models

[70]

N/A siRNA i.v. targeted nanoliposomes BLT humanized mouse [66]

N/A siRNA i.v. aptamer targeted RAG-hu [134]

RSV ALN-RSV01 siRNA i.n. Phase II completed [30]

N/A siRNA i.n. Murine model [11, 130]

EBOV N/A PMO i.p. Murine, guinea pig, non-

human primate models

[42, 115]

N/A siRNA SNALPs Non-human primate models [43]

Influenza N/A ODN i.v. liposome Murine model [55, 90]

N/A siRNA i.v. Murine Model [41, 110,

125, 132]

N/A siRNA i.n. Chickens [125]